Health & Fitness
Health and Fitness
Health and Fitness
Thu, November 8, 2012
Wed, November 7, 2012
VELscope Reaches 25 Million Oral Cancer Exams Milestone
November 07, 2012 09:00 ET
VELscope Reaches 25 Million Oral Cancer Exams Milestone
Maker of the World's Most Popular Adjunctive Oral Cancer Screening Technology Sees Much Opportunity for Further Growth
BURNABY, BRITISH COLUMBIA--(Marketwire - Nov. 7, 2012) - LED Medical Diagnostics Inc. (TSX VENTURE:LMD) -
LED Dental announced today that its VELscope® enhanced oral assessment technology has been used to conduct an estimated 25 million oral cancer exams since its 2006 introduction.
"We created our VELscope technology because we saw an opportunity to help the dental community make a profound impact on the health and mortality of millions of people," said Peter Whitehead, founder and CEO of LED Dental and its parent, LED Medical Diagnostics Inc. (TSX VENTURE:LMD). "We salute the dental professionals who have stepped up and added our technology to their screening protocol in order to provide the best possible oral health care for their patients."
Mr. Whitehead notes that as gratifying as it is to have contributed to 25 million adjunctive oral cancer screenings, there is much work yet to be done. "The fact is that the vast majority of dental practices are still not using any adjunctive screening technology," he said. "Moreover, patient surveys indicate that most practices are not even conducting the conventional oral cancer exam, which involves palpation of the face and neck and visual inspection of the oral cavity with the naked eye, on a regular basis."
LED recently announced that it has entered into a strategic alliance agreement to have DenMat Holdings (Lompoc, California) market and sell the VELscope Vx. Mr. Whitehead feels this development can accelerate sales of the award-winning VELscope Vx, the company's latest generation screening device. "DenMat gives us not only a strong direct sales focus and a proven ability to market innovative dental technologies," he said, "but a shared passion for collaborating with the dental community to improve the oral health of patients around the world." DenMat sells dental products in more than 60 countries.
The company's estimate that 25 million VELscope exams have been conducted is based on its internal sales figures and calculations provided by strategic marketing agency 14th Floor Solutions, LLC. The agency regularly conducts surveys of VELscope device owners asking such questions as how often VELscope exams are given, how effectively the VELscope works and how easy it is to use. These surveys have consistently revealed extremely high satisfaction levels, and the most recent one indicated that 95% of VELscope Vx users would recommend the device to a colleague.
About LED Medical Diagnostics Inc.
LED Medical Diagnostics Inc. was founded in 2003 and is headquartered in Burnaby, British Columbia, Canada. Its wholly-owned subsidiary, LED Dental Inc., is the manufacturer of the VELscope Vx enhanced oral assessment system. VELscope Vx devices, the first to apply tissue fluorescence visualization technology to the oral cavity, are used to conduct more screenings for oral cancer and other oral diseases than any adjunctive device in the world. For more information, call +1 (604) 434-4614, or visit [ www.velscope.com ].
About the VELscope Vx
The VELscope Vx is a powerful FDA- and Health Canada-approved tool used to screen for oral cancer. It saves lives by helping detect early stage oral cancer and pre-cancer and other abnormalities in the mouth such as viral, fungal and bacterial infections. The VELscope Vx is distributed in over 20 countries by its exclusive global distributor, DenMat Holdings. For more information please call +1 (604) 434-4614, or visit [ www.velscope.com ] or [ www.denmat.com ].
Forward-Looking Statements
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding the Company's future product sales and its future distribution strategy. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2011. This list is not exhaustive of the factors that may affect the Company's forward-looking information. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
